Navigation Links
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
Date:5/26/2011

ble, it may be unable to sustain profitability.
  • At March 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking state
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
    2. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
    3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
    4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
    5. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
    8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
    9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
    10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
    11. AmeriCares Presents Power of Partnership Award to Baxter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously ... be found at the junctures where layers ... world of nanotechnology, the interfaces between layers ... with applications in such high-tech favorites as ... the vast potential of these metal oxide ...
    (Date:1/15/2014)... NIAGARA FALLS, N.Y., Jan. 15, 2014 /PRNewswire/ ... announce that it has been selected by Buffalo ... component supplier in support of its SBIR Phase ... B3 has developed the only comprehensive air purification ... VOCs and other chemical pollutants, allergens and organic ...
    (Date:1/15/2014)... SAN JOSE, California , January 15, 2014 /PRNewswire/ ... developing antibody-drug conjugates for cancer, today announced the appointment ... of Directors. Dr Reynolds has over 20 years, development ... Chief Medical Officer at Seattle Genetics. "I ... for Oxford BioTherapeutics, as the company completes its transition ...
    (Date:1/15/2014)... 15, 2014 A study has ... races on the Formula 1 track could help to ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery ... is being funded by healthcare provider Simplyhealth. ... collect data about the on-track performance of Vodafone McLaren ...
    Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
    ... HOUSTON, Jan. 7 Cyberonics, Inc. (Nasdaq: CYBX ... the U.S. Food and Drug Administration ("FDA") to amend the ... treated with VNS TherapyTM.Based on a reassessment of the study ... to the data analysis originally specified in the study protocol, ...
    ... ALTO, Calif., Jan. 7 Intradigm Corporation, a ... today,announced that the company has closed the final ... led the $2.9 million tranche, with,existing investor, Lilly ... brings the total Series B financing to $21.4 ...
    ... TAMPA BAY, Fla., Jan. 7 News briefs concerning economic,and ... Bay Partnership: , Draper Labs Acquires ... The Charles Stark Draper Laboratory bought a 41,000-square-foot building,in St. ... Renovations to the building, 10050 16th St. N., should ...
    Cached Biology Technology:Cyberonics Provides Business Update on Depression Clinical Trial 2Cyberonics Provides Business Update on Depression Clinical Trial 3Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 2Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 3Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs) 4
    (Date:4/15/2014)... ITHACA, N.Y. If an insect drew a line ... would be a tangled mess. But there,s method to ... of mechanical engineering and physics, who tries to find ... Photo: https://cornell.box.com/tbeetle , It turns out the ... an optimal reorientation dance as it chases its prey ...
    (Date:4/15/2014)... the loveliest in the world, but they also contain ... have become enriched in cadmium. Grasses take up this ... cattle and sheep that graze them. The problem is ... worldwide. , The concern is that if cadmium concentrations ... human health and New Zealand,s agricultural economy could be ...
    (Date:4/15/2014)... world for which no pharmaceutical treatment exists. These include, ... in the tropics, as well as a type of ... easily spread by the hands and can be dangerous ... at Aalto University and the University of Eastern Finland ... spread of one type of virus into cells with ...
    Breaking Biology News(10 mins):Photo: Tiger beetle's chase highlights mechanical law 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2
    ... 2008 -- In a move that promises to change the ... unveiled a set of techniques for cleanly converting problematic biofuels ... research is available online in the journal Metabolic Engineering ... describe a new fermentation process that allows E. coli ...
    ... Southern Research Station (SRS) today announced that an SRS ... responsible for killing redbay and other trees in the ... Lead author and Iowa State University ... Stephen Fraedrich, and Azerbaijan National Academy of Sciences Researcher ...
    ... IMMEDIATE RELEASE The tummy,s taste for red wine ... Chemistry What happens when red wine meets red ... Israel are reporting, wine,s bounty of healthful chemical compounds may ... in the meat. The study, which reinforces the benefits of ...
    Cached Biology News:Research yields pricey chemicals from biodiesel waste 2Research yields pricey chemicals from biodiesel waste 3Tree-killing fungus officially named by scientists 2American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9